Evolutionary Tree Capital Management LLC Acquires Shares of 4,454 Intuitive Surgical, Inc. (NASDAQ:ISRG)

Evolutionary Tree Capital Management LLC bought a new position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) during the second quarter, HoldingsChannel reports. The institutional investor bought 4,454 shares of the medical equipment provider’s stock, valued at approximately $1,981,000. Intuitive Surgical accounts for approximately 2.0% of Evolutionary Tree Capital Management LLC’s investment portfolio, making the stock its 21st biggest holding.

Several other institutional investors and hedge funds have also made changes to their positions in ISRG. Advisors Asset Management Inc. grew its stake in shares of Intuitive Surgical by 18.1% during the first quarter. Advisors Asset Management Inc. now owns 7,380 shares of the medical equipment provider’s stock valued at $2,945,000 after acquiring an additional 1,129 shares in the last quarter. Public Employees Retirement System of Ohio grew its stake in Intuitive Surgical by 5.4% during the 4th quarter. Public Employees Retirement System of Ohio now owns 191,283 shares of the medical equipment provider’s stock valued at $64,531,000 after purchasing an additional 9,869 shares in the last quarter. HCR Wealth Advisors increased its holdings in Intuitive Surgical by 26.3% during the 4th quarter. HCR Wealth Advisors now owns 1,042 shares of the medical equipment provider’s stock worth $352,000 after purchasing an additional 217 shares during the last quarter. Artisan Partners Limited Partnership increased its holdings in Intuitive Surgical by 53.5% during the 4th quarter. Artisan Partners Limited Partnership now owns 63,851 shares of the medical equipment provider’s stock worth $21,541,000 after purchasing an additional 22,264 shares during the last quarter. Finally, SWP Financial LLC acquired a new position in shares of Intuitive Surgical in the 4th quarter valued at approximately $255,000. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Intuitive Surgical

In other news, Director Craig H. Barratt sold 1,400 shares of the stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total value of $641,382.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Intuitive Surgical news, Director Amal M. Johnson sold 2,943 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $443.30, for a total value of $1,304,631.90. Following the completion of the sale, the director now directly owns 12,275 shares in the company, valued at $5,441,507.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Craig H. Barratt sold 1,400 shares of Intuitive Surgical stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total value of $641,382.00. The disclosure for this sale can be found here. Insiders have sold 53,120 shares of company stock valued at $25,528,753 in the last quarter. Corporate insiders own 0.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Barclays raised their price target on shares of Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a research report on Thursday, July 18th. Redburn Atlantic raised shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $380.00 to $510.00 in a research report on Friday, August 2nd. Morgan Stanley upped their target price on shares of Intuitive Surgical from $375.00 to $460.00 and gave the company an “equal weight” rating in a research note on Monday, July 15th. Evercore ISI decreased their price target on Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating for the company in a research note on Friday, July 19th. Finally, JPMorgan Chase & Co. upped their price objective on Intuitive Surgical from $475.00 to $495.00 and gave the company an “overweight” rating in a research note on Friday, July 19th. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $446.45.

Intuitive Surgical Stock Performance

Intuitive Surgical stock opened at $486.20 on Friday. Intuitive Surgical, Inc. has a one year low of $254.85 and a one year high of $496.18. The company has a 50-day simple moving average of $468.01 and a 200-day simple moving average of $425.12. The firm has a market capitalization of $172.46 billion, a P/E ratio of 87.76, a P/E/G ratio of 5.41 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, topping the consensus estimate of $1.54 by $0.24. The firm had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. Intuitive Surgical’s quarterly revenue was up 14.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.18 EPS. As a group, sell-side analysts forecast that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.